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Microbiology and 3) Haematology, Departments of Medicine and Clinical
Research, University Hospital Basel, Basel, SwitzerlandAbstractScreening for Pseudomonas aeruginosa is recommended to guide
empirical antimicrobial therapy in patients on high-risk units.
However, evidence for this approach is scarce. We therefore
screened 1310 patients with severe haematologic diseases for
P. aeruginosa colonization at admission: 108 (8.2%) were positive,
but only nine (0.7%; six with the same clone as in the screening
isolate) subsequently developed a P. aeruginosa bloodstream
infection (positive predictive value of screening, 8.6%; negative
predictive value of screening, 99.5%). Routine screening for
P. aeruginosa at admission did not sufﬁciently predict subsequent
bloodstream infections caused by P. aeruginosa.
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ciated with a high mortality in immunocompromised patients [1].
International guidelines strongly recommend screening for
multidrug resistant (MDR) P. aeruginosa in patients on high-riskMicrobiol Infect 2015; 21: 572.e1–572.e3
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rationales for these recommendations are twofold: ﬁrstly, to
guide empirical antimicrobial treatment in subsequent invasive
infections, and secondly, to avoid transmission of MDR
P. aeruginosa by timely implementation of contact precautions. In
this study, we assessed the value of such a screening programme
on our haematologic reverse isolation unit (HRIU) to predict
subsequent bloodstream infections (BSI) caused by P. aeruginosa.
We performed a prospective observational study at the
University Hospital Basel, an 855-bed tertiary-care centre in
Switzerland. Our HRIU has 13 beds admitting mainly patients
for allogeneic/autologous stem cell transplantations. All rooms
are provided with high-ﬁltration laminar airﬂow. Standard
precautions include carriage of surgical masks upon room entry
and wearing gloves and gowns for direct patient contact. Stem
cell transplant recipients receive routine antimicrobial pro-
phylaxis with trimethoprim/sulfamethoxazole and ﬂuconazole.
Patients admitted to the HRIU from January 2002 through
December 2013 were routinely screened for P. aeruginosa
colonization by performance of rectal and oropharyngeal swabs
at admission and monthly thereafter. Patient data were pro-
spectively recorded in a database as part of the surveillance of
nosocomial infections.
Screening samples were cultured on selective cetrimide agar
at 42°C for 24 to 48 hours. Identiﬁcation of P. aeruginosa was
done on the basis of the oxidase reaction. In case of a positive
oxidase reaction and for all clinical isolates, biochemical proﬁles
obtained by the Vitek 2 GN card (bioMérieux, Durham, NC,
USA) were used for identiﬁcation. Resistance patterns of
P. aeruginosa blood culture isolates were classiﬁed as suggested
by Magiorakos et al. [4].
For molecular typing, DNA fragments were separated by
pulsed-ﬁeld gel electrophoresis after DraI digestion. In Dice
analysis, we deﬁned isolates of 90% similarity as clones.
One or more blood culture isolates of P. aeruginosa were
deﬁned as BSI. Clinical specimens positive for P. aeruginosa were
interpreted as infection if clinical judgment retrieved from
medical chart review and infectious disease consultation argued
for relevant infection. Hospital-acquired colonization was
deﬁned as a positive screening swab obtained 48 hours after
hospitalization in the presence of a negative screening swab at
admission (<48 hours). Possible hospital-acquired colonization
was deﬁned as a positive screening swab obtained 48 hours
after admission if no screening swab has been submitted to the
laboratory <48 hours after admission. Community-acquired
colonization was deﬁned as a positive screening swab ob-
tained <48 hours after admission.
The study was approved by the local ethic committee of
Basel as part of the quality assurance programme.ious Diseases. Published by Elsevier Ltd. All rights reserved
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hospitalized on the HRIU, of whom 1310 (84.6%) were
screened: 108 patients (8.2%) were colonized with P. aeruginosa
and nine (0.7%) subsequently developed a P. aeruginosa BSI
(Table 1). The positive and negative predictive values of the
screening for a subsequent P. aeruginosa BSI were 8.6% and
99.5%, respectively. Fifty-one patients were positive at admis-
sion, and 57 were detected only at a follow-up screening.
Colonization was classiﬁed as hospital-acquired in 37.0%, as
possibly hospital-acquired in 15.7% and as community-acquired
in 47.2%.
During the study period, P. aeruginosa was identiﬁed in 73
clinical specimens. Detection of P. aeruginosa was interpreted as
clinically relevant in 38 clinical specimens, accounting for 15
BSIs, seven skin and soft tissue infections, three urinary tract
infections, two upper respiratory tract infections, and ﬁve
lower respiratory tract infections. The remaining 35 isolates
were interpreted as colonization rather than infection. Of the
15 patients with a P. aeruginosa BSI, ﬁve had a MDR blood
culture isolate. Four of the 15 P. aeruginosa BSIs were related to
an infection at another site. Other types of invasive infections
were not detected. The overall incidence of BSIs caused by
P. aeruginosa was 1.0 per 100 patients and 0.3 per 1000 hos-
pitalization days. Two patients had a recurrence of BSI. The all-
cause in-hospital mortality in the 15 patients with a P. aeruginosa
BSI was 33.3% (5/15); death was directly attributable to the
P. aeruginosa BSI in 60.0% (3/5).
Overall, nine patients were colonized before developing the
BSI; six had the same clone detected as in the blood culture
isolate, two had their screening and blood culture isolates not
genotypically compared and one had a different clone detected
in the blood culture isolate. Three patients became colonized
only after the BSI, and the remaining three patients had a
repeatedly negative screening.
The rate of Gram-negative bacteraemia has increased in
stem cell transplant recipients [5]. In contrast, we observed a
low incidence of (MDR) P. aeruginosa BSIs and only few
noninvasive infections caused by P. aeruginosa. Knowing theTABLE 1. Colonization and subsequent bloodstream
infections with Pseudomonas aeruginosa in 1310 patients
screened for rectal/oropharyngeal colonization on a
haematologic reverse isolation unit
Screening
Bloodstream
infection
No bloodstream
infection
Positive 9 (0.7%) 96 (7.3%)
Negative 6 (0.5%) 1199 (91.5%)
Total number of colonized patients is 105 and not 108, as three patients had a positive
screening only after the bloodstream infection with Pseudomonas aeruginosa. Of the
15 patients with a P. aeruginosa bloodstream infection, three (33.3%) of nine
screening-positive and two (33.3%) of six screening-negative patients died.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Insusceptibility pattern of colonizing P. aeruginosa is helpful
because survival in P. aeruginosa BSI signiﬁcantly improves with
effective empiric antimicrobial therapy against P. aeruginosa [6].
P. aeruginosa BSIs were frequently preceded by rectal colo-
nization with the same clone present in the invasive isolates.
This observations contrasts results from a recent study in
which urine cultures have been shown to be the most effective
sampling site to detect P. aeruginosa carriage [7].
Amain limitation of our study is the fact that we solely analysed
patients of an isolation unit, where empirical antipseudomonal
antimicrobial therapy is standard of care for patients with neu-
tropenic fever. Our epidemiologic data and conclusions might
therefore not be generalizable to other high-risk populations.
However, on units without strict contact precautions, cross-
transmission events during hospitalization might play a more
important role in the acquisition of P. aeruginosa, which would
further decrease the value of an admission screening for
P. aeruginosa. In epidemiologic studies of intensive care patients, up
to 60% of all colonization/infection episodes with P. aeruginosa
were shown to be due to cross-transmission [8–10].
In conclusion, routine screening for P. aeruginosa at admis-
sion did not sufﬁciently predict subsequent BSIs caused by
P. aeruginosa. Routine P. aeruginosa screening should primarily
be performed in outbreak settings and on units with a high
burden of MDR P. aeruginosa.Transparency declarationThe authors declare that they have no conﬂicts of interest.AcknowledgementsWe thank E. Schultheiss, laboratory technician, Division of
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